Kiora Pharmaceuticals, Inc.
KPRX
$3.32
$0.03090.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -353.42% | 45.27% | |||
| Gross Profit | 353.42% | -48.55% | |||
| SG&A Expenses | -3.92% | -10.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.12% | 10.37% | |||
| Operating Income | 7.12% | -11.28% | |||
| Income Before Tax | 36.76% | -53.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.74% | -53.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.74% | -53.64% | |||
| EBIT | 7.12% | -11.28% | |||
| EBITDA | 7.26% | -11.49% | |||
| EPS Basic | -23.65% | -52.02% | |||
| Normalized Basic EPS | 20.69% | -18.16% | |||
| EPS Diluted | -23.65% | -52.06% | |||
| Normalized Diluted EPS | 20.69% | -18.16% | |||
| Average Basic Shares Outstanding | 0.08% | 1.06% | |||
| Average Diluted Shares Outstanding | 0.08% | 1.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||